CD276 and breast carcinoma: Our data show B7-H3 to be expressed in both BC and BrM tumours, thus investigating the efficacy of targeting B7-H3 using CAR T cells, or by using antibody-drug-conjugates, will be an important next step in understanding the therapeutic potential of B7-H3 in breast cancer and breast cancer brain metastases.